Merrimack Pharmaceuticals announced it will discontinue the development of an experimental treatment for pancreatic cancer after the drug failed to meet the main and secondary goals of a mid-stage trial.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.